Inhibrx Biosciences INBX
NASDAQ INBX
$90.61 -1.13 (-1.23%)
At close: Nov 10, 2026 · 4:00 PM EST

Inhibrx Biosciences (INBX) EBITDA (2023 - 2026)

Updated

Inhibrx Biosciences (INBX) posted EBITDA of -$31.63 million for Q2 2026, compared with -$26.1 million a year earlier.

Analysis

Inhibrx Biosciences (INBX) EBITDA (2023 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, EBITDA at Inhibrx Biosciences was -$120.04 million; for FY2025, it was -$130.1 million.

  • In prior years, Inhibrx Biosciences' EBITDA was -$327.1 million in FY2024 and -$213.13 million in FY2023.
  • Quarterly EBITDA has run from a low of -$159.6 million in Q2 2024 to a high of -$26.1 million in Q2 2025 over five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn 13.33 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 8.30 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 8.16 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn 7.37 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn -
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn -
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 4.83 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 4.20 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn 7.05 Bn
10 Inhibrx Biosciences 1.45 Bn 882.42 Mn - -30.34 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -31.63 Mn
Dec 31, 2025 -29.72 Mn
Sep 30, 2025 -32.59 Mn
Jun 30, 2025 -26.10 Mn
Mar 31, 2025 -41.69 Mn
Dec 31, 2024 -49.24 Mn
Sep 30, 2024 -46.04 Mn
Jun 30, 2024 -159.60 Mn
Mar 31, 2024 -72.22 Mn
Dec 31, 2023 -86.74 Mn
Sep 30, 2023 -44.28 Mn
Jun 30, 2023 -41.04 Mn
API Access

Inhibrx Biosciences EBITDA API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda&ticker=INBX&period=max&api_key=YOUR_API_KEY